Salud financiera de hoja de balance de Dicot

Salud financiera controles de criterios 4/6

Dicot tiene un patrimonio de los accionistas total de SEK44.4M y una deuda total de SEK0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son SEK53.6M y SEK9.2M respectivamente.

Información clave

Ratio deuda-patrimonio

kr0

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	kr32.03m
Patrimonio	kr30.75m
Total pasivo	kr7.84m
Activos totales	kr38.59m

Actualizaciones recientes sobre salud financiera

We're Keeping An Eye On Dicot's (NGM:DICOT) Cash Burn Rate

Apr 09

We Think Dicot (NGM:DICOT) Needs To Drive Business Growth Carefully

Dec 23

Recent updates

We're Keeping An Eye On Dicot's (NGM:DICOT) Cash Burn Rate

Apr 09

We Think Dicot (NGM:DICOT) Needs To Drive Business Growth Carefully

Dec 23

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (SEK53.5M) de DICOT superan a sus pasivos a corto plazo (SEK9.2M).

Pasivo a largo plazo: DICOT no tiene pasivos a largo plazo.

Historial y análisis de deuda-patrimonio

Nivel de deuda: DICOT está libre de deudas.

Reducción de la deuda: DICOT no tenía deudas hace 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: DICOT tiene menos de un año de cash runway basado en su flujo de caja libre actual.

Pronóstico de cash runway: DICOT tiene menos de un año de cash runway si el flujo de caja libre sigue reduciéndose a tasas históricas de 28.4% cada año

Salud financiera de hoja de balance de Dicot

Salud financiera controles de criterios 4/6

Información clave

Actualizaciones recientes sobre salud financiera

We're Keeping An Eye On Dicot's (NGM:DICOT) Cash Burn Rate

We Think Dicot (NGM:DICOT) Needs To Drive Business Growth Carefully

Dicot Ordinary Shares to Be Deleted from Other OTC

Recent updates

Dicot AB (publ) Announces Positive Safety and Improved Efficacy Results from Phase 1 Study

We're Keeping An Eye On Dicot's (NGM:DICOT) Cash Burn Rate

Dicot AB (publ) to Report Q1, 2024 Results on May 06, 2024

Dicot AB (publ) Announces Recruitment Completed in Dicot's Phase 1 Trial

New major risk - Financial position

Dicot AB (publ) to Report Fiscal Year 2023 Results on Feb 26, 2024

Dicot AB (publ) Presents Positive Results from the First Part of its Phase 1 Clinical Study

Dicot Applies for Patent Covering New Manufacturing Technology

We Think Dicot (NGM:DICOT) Needs To Drive Business Growth Carefully

Dicot AB (publ) Announces Partial Results from Phase 1 Trial to Be Presented Early Next Year

Director exercised options to buy kr169k worth of stock.

New minor risk - Share price stability

Dicot AB, Annual General Meeting, May 06, 2024

Dicot AB Initiates Repeated Dosing in Phase I Study

The Second Part of Dicot's Phase 1 Study Starts on October 20, 2023

Dicot AB to Report Q3, 2023 Results on Oct 31, 2023

Dicot AB Applies for International Patent Protection

Dicot AB Announces First Participants Dosed in Phase 1 Trial

Dicot AB Applies for US Patent

Dicot AB (publ) Announces Clinical Phase 1 Study Starts

Dicot AB Receives Approval to Start Phase 1 Clinical Trial

Dicot AB to Report Q2, 2023 Results on Aug 24, 2023

Director exercised options to buy kr194k worth of stock.

New major risk - Share price stability

Dicot AB (publ) Submits Application to Start Clinical Phase 1 Trial

Dicot to Seek Initiation of a Phase I Clinical Trial for the Drug Candidate Lib-01

Dicot's Study Drug Arrives in Sweden

Dicot AB Appoints Mats Silvander as New chief technical officer

Dicot AB Study Results Presented at European Society for Sexual Medicine

Dicot AB to Report Fiscal Year 2022 Results on Feb 27, 2023

No independent directors

Dicot AB Announces That It's Latest Study of the Mechanism of Action of LIB-01 Assumed to Be the Next Generation of Potency Drugs

Dicot AB Announces Successful First Regulatory Meeting for LIB-01

Dicot AB to Report Q3, 2022 Results on Nov 15, 2022

Dicot AB Reports Good Results from Preclinical Toxicology Studies

Dicot AB to Report Q2, 2022 Results on Aug 25, 2022

Dicot AB Moves Forward with New Patent Application

First quarter 2022 earnings released

No independent directors

Dicot AB Appoints Charlotta Gauffin as Chief Scientific Officer

Dicot AB Announces Board Changes

Dicot to Develop LIB-01 to an Oral Drug

Dicot AB Announces CEO Changes

Dicot Announces CFO Changes, Effective March 7, 2022

Dicot Announces That the Results of Dicot's Drug Candidate Will Be Presented At the European Society for Sexual Medicine

Dicot AB Announces Election of Eva Sjökvist Saers as the Chairman of Board, At the Extraordinary General Meeting Held on February 9, 2021

Dicot AB (publ) Broadens Testing of the Drug Candidate LIB-01

New 90-day low: kr0.94

Dicot Initiates Toxicology Studies Before Applying for Clinical Trials

New 90-day low: kr0.99

New 90-day low: kr1.06

Dicot Ordinary Shares to Be Deleted from Other OTC

New 90-day low: kr1.11

New 90-day low: kr1.33

Dicot AB Continues Studies with Pelvipharm to Generate Knowledge About Treatment Times, Doses and Libiguin's® Mechanism of Action

Dicot AB Announces That Sustainable Supply of Raw Material Important to Dicot

Dicot AB to Report Q2, 2020 Results on Aug 27, 2020

New 90-day high - kr2.45

Dicot AB to Report Q3, 2020 Results on Nov 23, 2020

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Análisis de cash runway

Descubre empresas con salud financiera